Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Julphar
Covington
Federal Trade Commission
Mallinckrodt
Baxter
Teva
Fish and Richardson
AstraZeneca

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,773,720

« Back to Dashboard

Which drugs does patent 6,773,720 protect, and when does it expire?

Patent 6,773,720 protects LIALDA and is included in one NDA.

This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 6,773,720
Title: Mesalazine controlled release oral pharmaceutical compositions
Abstract:Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of substances with a melting point below 90.degree. C. in which the active ingredient is at least partly inglobated; b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed; c) optionally other excipients.
Inventor(s): Villa; Roberto (Panama, PA), Pedrani; Massimo (Panama, PA), Ajani; Mauro (Panama, PA), Fossati; Lorenzo (Panama, PA)
Assignee: Cosmo S.p.A. (Milan, IT)
Application Number:10/009,491
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,773,720
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Process;

Drugs Protected by US Patent 6,773,720

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire LIALDA mesalamine TABLET, DELAYED RELEASE;ORAL 022000-001 Jan 16, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,773,720

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI99A1316Jun 14, 1999
PCT Information
PCT FiledJune 08, 2000PCT Application Number:PCT/EP00/05321
PCT Publication Date:December 21, 2000PCT Publication Number: WO00/76481

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Mallinckrodt
Cipla
Deloitte
Queensland Health
US Department of Justice
Cerilliant
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.